Sunday, May 31, 2015

Genentech’s Perjeta Regimen Helped People with HER2-positive Early Breast Cancer Live Longer without Their Disease Returning or Getting Worse Compared to Herceptin and Chemotherapy

… About Breast Cancer Breast cancer is the most common cancer … with breast cancer. HER2-positive cancer is a particularly aggressive form of breast cancer. About Genentech in HER2-positive Breast Cancer Genentech has spent …

No comments:

Post a Comment